Results for tag: "Alpha L Iduronidase"

Alpha-L-Iduronidase (also known as IDUA) is an enzyme that is involved in the breakdown of glycosaminoglycans (GAGs). It is a lysosomal enzyme that is responsible for the degradation of GAGs, which are essential components of the extracellular matrix. Deficiencies in this enzyme can lead to a range of diseases, including mucopolysaccharidosis type I (MPS I). Enzyme replacement therapy (ERT) is the primary treatment for MPS I, and Alpha-L-Iduronidase is the enzyme used in this therapy. The Alpha-L-Iduronidase market is a rapidly growing market, driven by the increasing prevalence of MPS I and the growing demand for ERT. The market is expected to grow at a steady rate in the coming years, driven by the increasing awareness of MPS I and the availability of new treatments. Some of the major companies in the Alpha-L-Iduronidase market include Sanofi, Shire, Pfizer, and Genzyme. These companies are involved in the development and manufacture of Alpha-L-Iduronidase for the treatment of MPS I. Show Less Read more